Damien Urban

2.2k total citations
59 papers, 1.2k citations indexed

About

Damien Urban is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Damien Urban has authored 59 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Damien Urban's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (21 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Damien Urban is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (21 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Damien Urban collaborates with scholars based in Israel, Australia and United States. Damien Urban's co-authors include Jair Bar, Benjamin Solomon, Amir Onn, Danny Rischin, June Corry, Mathias Bressel, Teodor Gottfried, Elizabeth Dudnik, Yaacov Richard Lawrence and Sameh Daher and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Damien Urban

58 papers receiving 1.2k citations

Peers

Damien Urban
Eun Joo Kang South Korea
Damien Urban
Citations per year, relative to Damien Urban Damien Urban (= 1×) peers Eun Joo Kang

Countries citing papers authored by Damien Urban

Since Specialization
Citations

This map shows the geographic impact of Damien Urban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damien Urban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damien Urban more than expected).

Fields of papers citing papers by Damien Urban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damien Urban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damien Urban. The network helps show where Damien Urban may publish in the future.

Co-authorship network of co-authors of Damien Urban

This figure shows the co-authorship network connecting the top 25 collaborators of Damien Urban. A scholar is included among the top collaborators of Damien Urban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damien Urban. Damien Urban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moskovitz, Mor, Sivan Shamai, Barliz Waissengrin, et al.. (2023). P2.07-09 Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?. Journal of Thoracic Oncology. 18(11). S327–S327. 1 indexed citations
2.
Sagie, Shira, et al.. (2023). Early death after a diagnosis of metastatic solid cancer–raising awareness and identifying risk factors from the SEER database. PLoS ONE. 18(9). e0281561–e0281561. 3 indexed citations
3.
Urban, Damien, et al.. (2023). Fast vs. Regular Track for Lung and Pancreatic Cancer Diagnosis—Time from Initial Finding to Final Diagnosis and Patient Survival. Journal of Medical Systems. 47(1). 48–48. 1 indexed citations
4.
Tur‐Sinai, Aviad, Damien Urban, Daniel Azoulay, Gil Bar‐Sela, & Netta Bentur. (2022). Understanding out-of-pocket spending and financial hardship among patients who succumb to cancer and their caregivers. Israel Journal of Health Policy Research. 11(1). 1–1. 5 indexed citations
5.
Shamai, Sivan, Barliz Waissengrin, Damien Urban, et al.. (2022). 41P Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world study. Annals of Oncology. 33. S51–S51. 2 indexed citations
7.
Bar, Jair, Damien Urban, Uri Amit, et al.. (2021). Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades. Journal of Oncology. 2021. 1–10. 25 indexed citations
8.
Moskovitz, Mor, Damien Urban, Hovav Nechushtan, et al.. (2021). dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%. Clinical Lung Cancer. 23(2). 122–134. 17 indexed citations
9.
Tur‐Sinai, Aviad, Damien Urban, & Netta Bentur. (2020). Out‐of‐pocket spending of deceased cancer patients in five European countries and Israel. European Journal of Cancer Care. 30(2). e13372–e13372. 4 indexed citations
10.
Magri, Valentina, Teodor Gottfried, Mattia Di Segni, et al.. (2019). <p>Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients</p>. Cancer Management and Research. Volume 11. 8201–8207. 39 indexed citations
11.
Dudnik, Elizabeth, Jair Bar, Mor Moskovitz, et al.. (2019). P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi. Journal of Thoracic Oncology. 14(10). S760–S760. 1 indexed citations
12.
Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2019). OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data. Journal of Thoracic Oncology. 14(10). S235–S236. 6 indexed citations
13.
Bar, Jair, Efrat Ofek, Iris Barshack, et al.. (2019). Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer. 138. 109–115. 44 indexed citations
14.
Solomon, Benjamin, Richard J. Young, Mathias Bressel, et al.. (2019). Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. Annals of Oncology. 30(10). 1638–1646. 30 indexed citations
15.
Solomon, Benjamin, Richard J. Young, Mathias Bressel, et al.. (2018). Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. Cancer Immunology Research. 6(3). 295–304. 100 indexed citations
16.
Sella, Tal, et al.. (2015). Preferences for disclosure of disease related information among thoracic cancer patients. Lung Cancer. 88(1). 100–103. 4 indexed citations
17.
Young, Richard J., Damien Urban, Christopher Angel, et al.. (2015). Frequency and prognostic significance of p16INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma. British Journal of Cancer. 112(6). 1098–1104. 67 indexed citations
18.
Waissengrin, Barliz, et al.. (2014). Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience. Journal of Pain and Symptom Management. 49(2). 223–230. 69 indexed citations
19.
Bar, Jair, Maya Damianovich, Yoram Cohen, et al.. (2013). Genetic Mutation Screen in Early Non–Small-Cell Lung Cancer (NSCLC) Specimens. Clinical Lung Cancer. 15(2). 159–165. 15 indexed citations
20.
Urban, Damien, et al.. (2013). Suicide in Lung Cancer. CHEST Journal. 144(4). 1245–1252. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026